Cargando…

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity

The NETTER-1 trial demonstrated significantly improved progression-free survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) emphasizing the high demand for response prediction in appropriate candidates. In this multicenter study, we aimed to elucidate the p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Werner, Rudolf A., Lapa, Constantin, Ilhan, Harun, Higuchi, Takahiro, Buck, Andreas K., Lehner, Sebastian, Bartenstein, Peter, Bengel, Frank, Schatka, Imke, Muegge, Dirk O., Papp, László, Zsótér, Norbert, Große-Ophoff, Tobias, Essler, Markus, Bundschuh, Ralph A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351689/ https://www.ncbi.nlm.nih.gov/pubmed/27705948 http://dx.doi.org/10.18632/oncotarget.12402

Ejemplares similares

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction
por: Khurshid, Zain, et al.
Publicado: (2018)

Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy
por: Pyka, Thomas, et al.
Publicado: (2015)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers
por: Weich, Alexander, et al.
Publicado: (2022)

Volumetric and texture analysis of pretherapeutic (18)F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib
por: Werner, Rudolf A., et al.
Publicado: (2018)

Somatostatin Receptor Based Imaging and Radionuclide Therapy
por: Xu, Caiyun, et al.
Publicado: (2015)

Radionuclide Imaging of Neurohormonal System of the Heart
por: Chen, Xinyu, et al.
Publicado: (2015)

In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target
por: Şen, Feyza, et al.
Publicado: (2023)

Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?
por: Wetz, Christoph, et al.
Publicado: (2020)

The next era of renal radionuclide imaging: novel PET radiotracers
por: Werner, Rudolf A., et al.
Publicado: (2019)

High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging
por: Buder, Kristina, et al.
Publicado: (2014)

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

The assessment of left ventricular mechanical dyssynchrony from gated (99m)Tc-tetrofosmin SPECT and gated (18)F-FDG PET by QGS: a comparative study
por: Lehner, Sebastian, et al.
Publicado: (2021)

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
por: Bison, Sander M., et al.
Publicado: (2014)

Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
por: Cullinane, Carleen, et al.
Publicado: (2020)

Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI
por: Lapa, Constantin, et al.
Publicado: (2016)

Tumor-Associated Macrophages in Glioblastoma Multiforme—A Suitable Target for Somatostatin Receptor-Based Imaging and Therapy?
por: Lapa, Constantin, et al.
Publicado: (2015)

Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients
por: Lapa, Constantin, et al.
Publicado: (2018)

The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
por: Wetz, Christoph, et al.
Publicado: (2019)

Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Derlin, Thorsten, et al.
Publicado: (2021)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response
por: Feijtel, Danny, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
por: Ahmadi Bidakhvidi, Niloefar, et al.
Publicado: (2021)

Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models
por: Ullrich, Martin, et al.
Publicado: (2023)

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
por: Shi, Mengqi, et al.
Publicado: (2022)

Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor–Directed Molecular Imaging and Therapy
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4–Directed Molecular Imaging and Therapy
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvements
por: Chen, Xinyu, et al.
Publicado: (2020)

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications
por: Werner, Rudolf A., et al.
Publicado: (2018)

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
por: Mileva, Magdalena, et al.
Publicado: (2020)

Effects of the Minimal Extrathyroidal Extension on Early Response Rates after (Adjuvant) Initial Radioactive Iodine Therapy in PTC Patients
por: Ahmaddy, Freba, et al.
Publicado: (2020)

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
por: Werner, R.A., et al.
Publicado: (2015)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2017)

Quantitative myocardial perfusion SPECT/CT for the assessment of myocardial tracer uptake in patients with three-vessel coronary artery disease: Initial experiences and results
por: Lehner, Sebastian, et al.
Publicado: (2021)

High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with (18)F-DCFPyL
por: Werner, Rudolf A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bqfi1tud51mfjurmsb9sam6fbm